Perkidopa100 mg+10 mg

Perkidopa 100 mg+10 mg is a combination antiparkinsonian medicine used to treat conditions involving dopamine deficiency in the brain.

Established/FDA-approved uses

• Idiopathic Parkinson's disease (paralysis agitans) — the primary indication, for relief of rigidity, bradykinesia (slowness of movement), tremor, and postural instability.
• Post-encephalitic parkinsonism — parkinsonism occurring after encephalitis.
• Symptomatic parkinsonism following carbon monoxide poisoning or manganese intoxication.

Off-label use

• Occasionally used off-label, at lower doses, for moderate-to-severe restless legs syndrome when other therapies are unsuitable; this use should only be directed by a physician, as intermittent dosing of Perkidopa 100 mg+10 mg in restless legs syndrome carries a risk of symptom augmentation.

Perkidopa 100 mg+10 mg is not effective for drug-induced (secondary) parkinsonism caused by antipsychotic medicines, and is not a cure — it controls symptoms only for as long as it is taken.

Perkidopa 100 mg+10 mg tablets combine two active ingredients in a fixed-dose combination:

• Levodopa — a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain.
• Carbidopa — a peripheral decarboxylase inhibitor that prevents breakdown of levodopa outside the brain.

Common strength combinations marketed include 100 mg/25 mg, 250 mg/25 mg, 100 mg/10 mg, and 50 mg/12.5 mg (levodopa/carbidopa), available as immediate-release and controlled/extended-release tablets, in accordance with local formulary availability.

Perkidopa 100 mg+10 mg is a fixed-dose combination used in the long-term management of Parkinson's disease and related parkinsonian syndromes. Levodopa is converted in the brain to dopamine, replenishing the dopamine deficiency that underlies Parkinson's disease symptoms. Carbidopa itself has no antiparkinsonian effect; instead, it blocks the breakdown of levodopa in the bloodstream and peripheral tissues before it can reach the brain.

By combining levodopa with carbidopa, a much smaller dose of levodopa is needed to achieve the same clinical effect compared with levodopa given alone, which reduces peripheral side effects such as nausea and vomiting and allows for faster dose titration. Perkidopa 100 mg+10 mg does not slow, halt, or reverse the underlying progression of Parkinson's disease; it controls symptoms only while treatment continues.

Parkinson's disease results from degeneration of dopamine-producing neurons in the substantia nigra of the brain. Dopamine itself cannot cross the blood-brain barrier, so it cannot be given directly as a drug.

Levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier. Once inside the central nervous system, it is decarboxylated to dopamine by the enzyme dopa-decarboxylase, replenishing depleted striatal dopamine stores and improving motor symptoms.

When levodopa is given alone, most of an oral dose is decarboxylated to dopamine in peripheral tissues (gut wall, liver, kidney) before it ever reaches the brain, producing high peripheral dopamine levels responsible for nausea, vomiting, and cardiovascular side effects, and leaving only a small fraction of the dose available centrally.

Carbidopa inhibits peripheral dopa-decarboxylase but does not cross the blood-brain barrier itself, so it does not interfere with the conversion of levodopa to dopamine within the brain. By blocking peripheral breakdown, carbidopa increases the fraction of an administered levodopa dose that reaches the central nervous system, permits use of substantially lower levodopa doses, and reduces peripheral (gastrointestinal and cardiovascular) side effects.

Perkidopa 100 mg+10 mg is taken by mouth, generally in 3–4 divided doses per day as directed by the physician. It may be taken with or without food, but a high-protein meal can reduce and slow absorption of the levodopa component, so patients should try to take Perkidopa 100 mg+10 mg at a consistent time relative to meals each day rather than switching timing unpredictably. Extended-release tablets should be swallowed whole (not crushed or chewed) unless the physician instructs otherwise. Doses should be spaced evenly through the day as prescribed, and the medicine should never be stopped or its dose reduced abruptly without medical advice (see Precautions and Warnings for the risk of a serious withdrawal reaction).

The following are well-documented, clinically significant interactions with Perkidopa 100 mg+10 mg:

• Non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine): contraindicated in combination — risk of hypertensive crisis (see Contraindications). A non-selective MAOI must be stopped at least 2 weeks before starting Perkidopa 100 mg+10 mg. Selective MAO-B inhibitors (e.g., selegiline at recommended doses) may be used with caution but can increase risk of severe orthostatic hypotension.
• Antihypertensive medicines: symptomatic postural (orthostatic) hypotension may occur when Perkidopa 100 mg+10 mg is added; blood pressure should be monitored and the antihypertensive dose adjusted if needed.
• Dopamine-receptor antagonists (e.g., typical and some atypical antipsychotics such as phenothiazines, butyrophenones, risperidone) and metoclopramide: may reduce the antiparkinsonian effectiveness of Perkidopa 100 mg+10 mg by blocking dopamine receptors; metoclopramide may also increase levodopa's bioavailability while antagonizing its central effect.
• Iron salts (oral iron supplements): can form chelates with levodopa and carbidopa in the gut, reducing their bioavailability; separate dosing times if both must be used.
• Phenytoin and papaverine: may reduce or reverse the therapeutic effect of levodopa.
• Isoniazid: may reduce the effectiveness of levodopa.
• Dopamine-depleting agents (e.g., reserpine, tetrabenazine): may reduce the effect of Perkidopa 100 mg+10 mg; avoid concurrent use where possible.
• Tricyclic antidepressants: rare reports of hypertension and dyskinesia when combined with Perkidopa 100 mg+10 mg.
• High-protein meals taken at the same time can reduce and delay absorption of levodopa (a food-drug interaction rather than a drug-drug interaction) — keep meal timing relative to doses consistent.

Always inform the prescribing physician of all other medicines, supplements, and herbal products being used before starting Perkidopa 100 mg+10 mg.

Side effects of Perkidopa 100 mg+10 mg can be dose-related and often overlap with disease-related symptoms. Report new or worsening symptoms to a physician.

Very common/common

• Nausea, vomiting, loss of appetite
• Dyskinesias (choreiform, dystonic, and other involuntary movements) — usually appear after months of therapy and are dose-related
• Dizziness, drowsiness, headache
• Dry mouth, constipation, diarrhea
• Dark discoloration of saliva, sweat, or urine (harmless)

Less common but clinically important

• Orthostatic (postural) hypotension, palpitations, cardiac arrhythmia
• Hallucinations, confusion, vivid dreams, psychotic-like behavior (see Precautions)
• Impulse control disorders — compulsive gambling, hypersexuality, compulsive eating or shopping (see Precautions)
• Depression, sometimes with suicidal ideation
• Sudden onset of sleep during daily activities
• "On-off" phenomenon (unpredictable fluctuations between mobility and immobility) with long-term use
• Upper gastrointestinal bleeding in patients with a history of peptic ulcer disease

Rare

• Blood disorders (hemolytic and non-hemolytic anemia, leukopenia, thrombocytopenia, agranulocytosis)
• Elevated liver enzymes
• Severe allergic reactions (rash, angioedema)

Pregnancy: There are no adequate and well-controlled studies of Perkidopa 100 mg+10 mg in pregnant women. Animal reproduction studies have shown variable findings, including fetal malformations in some species at certain doses. Levodopa is known to cross the placenta. Perkidopa 100 mg+10 mg should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under a physician's supervision.

Lactation: Levodopa has been detected in human breast milk. Because of the potential for adverse effects in a nursing infant, a decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue the medicine, taking into account the importance of treatment to the mother.

The following precautions and warnings apply to treatment with Perkidopa 100 mg+10 mg:

• Do not stop abruptly. Sudden discontinuation or rapid dose reduction of Perkidopa 100 mg+10 mg can cause a syndrome resembling neuroleptic malignant syndrome, with high fever, muscle rigidity, altered consciousness, and autonomic instability. Any change in dose, or perioperative management, should be directed by a physician, with gradual tapering when discontinuation is necessary.
• Impulse control disorders: Perkidopa 100 mg+10 mg and other dopaminergic medicines can cause intense urges to gamble, increased sexual urges, compulsive spending, or binge eating, which patients may not recognize as drug-related. Patients and caregivers should be asked specifically about these behaviors at follow-up; dose reduction or discontinuation may be needed if they occur.
• Orthostatic hypotension: Perkidopa 100 mg+10 mg can cause a drop in blood pressure on standing, with dizziness or fainting, particularly when starting or increasing the dose or when combined with antihypertensive drugs. Rise slowly from sitting or lying positions.
• Hallucinations and psychosis: New or worsening hallucinations, confusion, or psychotic-like behavior can occur, particularly in elderly patients or with advancing disease; use with special caution in patients with a history of psychosis, and avoid in patients with major psychotic disorders.
• Dyskinesias: Long-term use of Perkidopa 100 mg+10 mg is commonly associated with dose-related involuntary movements (dyskinesias); dose adjustment may be required as therapy continues.
• Sudden onset of sleep: Some patients have reported falling asleep suddenly during activities of daily living, including driving, sometimes without warning. Patients should be assessed for excessive daytime drowsiness and cautioned about driving or operating machinery until their response to Perkidopa 100 mg+10 mg is known.
• Timing with high-protein meals: Large amounts of dietary protein taken at the same time can reduce and delay absorption of the levodopa component; a consistent daily pattern of dosing relative to meals is advised.
• Narrow-angle glaucoma: Contraindicated (see Contraindications). In chronic wide-angle (open-angle) glaucoma, Perkidopa 100 mg+10 mg may be used with caution and regular monitoring of intraocular pressure.
• Melanoma: Patients with Parkinson's disease have a higher background risk of melanoma. Any suspicious skin lesion should be evaluated before starting Perkidopa 100 mg+10 mg, and patients should have periodic skin examinations by a qualified professional during treatment.
• Depression and suicidal ideation: Observe patients for new or worsening depression, including suicidal thinking.
• Cardiovascular disease: Use with caution in patients with a history of myocardial infarction, cardiac arrhythmia, or severe cardiopulmonary disease; monitor cardiac function closely, especially during initial dose titration.
• Peptic ulcer disease: Use with caution — Perkidopa 100 mg+10 mg has been associated with upper gastrointestinal bleeding in patients with a history of peptic ulcer.
• Laboratory test interference: Perkidopa 100 mg+10 mg may cause false-positive results for urinary ketone bodies and false-negative results for urinary glucose with glucose-oxidase test methods; it may also cause a transient rise in liver enzymes, BUN, creatinine, or uric acid on routine blood tests.

Signs of Perkidopa 100 mg+10 mg overdose may include severe dyskinesias (involuntary movements), confusion, agitation, hallucinations, marked drops or rises in blood pressure, cardiac arrhythmia, and other exaggerated adverse effects.

In case of suspected overdose, seek immediate medical attention or contact emergency services / a poison control center right away. Management is supportive and should be carried out by medical professionals — this typically includes close monitoring of heart rhythm (ECG), careful attention to fluid and airway status, and general supportive care. Do not attempt to manage a suspected overdose at home; do not induce vomiting or give any treatment without professional medical guidance, as specific measures depend on the clinical situation.

Store at room temperature (below 30°C), protected from light and moisture. Do not use if the blister/packaging is torn or damaged. Keep out of reach of children.

Elderly: A large proportion of patients treated with Perkidopa 100 mg+10 mg are elderly. No age-related change in overall safety/efficacy has been established, but elderly patients may be more sensitive to certain adverse effects, particularly hallucinations, confusion, and orthostatic hypotension. No specific dose adjustment is defined by age alone; titrate carefully based on individual response and tolerability.

Renal impairment: No formal dosage adjustment has been established; use with caution and monitor closely, titrating slowly.

Hepatic impairment: No formal dosage adjustment has been established; use with caution in patients with significant liver disease.

Psychiatric history: Use with particular caution in patients with a history of psychosis, severe depression, or cardiovascular/pulmonary disease (see Precautions and Warnings).

Pediatric patients: Not recommended (see Pediatric Uses).

Perkidopa 100 mg+10 mg is generally used long-term, as Parkinson's disease is a chronic, progressive condition and the medicine controls symptoms only for as long as it is taken. Dosing is typically re-titrated periodically by the treating physician as the disease progresses and as tolerance to side effects or fluctuations in response (such as "wearing-off" or "on-off" phenomena) develop. Treatment should not be stopped or the dose reduced without medical supervision, given the risk of a severe withdrawal reaction (see Precautions and Warnings). There is no fixed maximum duration; therapy continues as long as it remains clinically beneficial and is periodically reviewed by the prescriber.

Antiparkinsonian agent — combination of a dopamine precursor (Levodopa) with a peripheral aromatic-L-amino-acid decarboxylase inhibitor (Carbidopa).

Levodopa, the component of Perkidopa 100 mg+10 mg responsible for the therapeutic effect, crosses the blood-brain barrier and is converted by dopa-decarboxylase into dopamine within the brain, replenishing dopamine stores depleted by the neurodegeneration of Parkinson's disease and thereby improving rigidity, bradykinesia, and tremor. Carbidopa, which does not cross the blood-brain barrier, inhibits dopa-decarboxylase in peripheral tissues only, preventing premature conversion of levodopa to dopamine outside the brain. This increases the amount of levodopa available to enter the central nervous system, allows lower overall levodopa doses, and markedly reduces peripheral dopamine-related side effects such as nausea.

C

Safety and effectiveness of Perkidopa 100 mg+10 mg in patients under 18 years of age have not been established. Perkidopa 100 mg+10 mg is not recommended for use in the pediatric population.